Expression Profile of Endoglin in Different Grades of Endometrial Cancer

被引:14
作者
Oplawski, Marcin [1 ,2 ]
Dziobek, Konrad [2 ]
Adwent, Iwona [3 ]
Dftbru, Dariusz [3 ]
Grabarek, Beniamin [1 ]
Zmarzly, Nikola [1 ]
Plewka, Andrzej [1 ,4 ]
Boron, Dariusz [2 ,3 ,5 ]
机构
[1] Med Univ Silesia, Sch Pharm, Dept Mol Biol, Div Lab Med Sosnowiec, Sosnowiec, Poland
[2] Ludwik Rydygier Mem Specialist Hosp, Dept Gynecol & Obstet Gynecol Oncol, Krakow, Poland
[3] Opole Med High Sch, Dept Midwifery, Opole, Poland
[4] Publ Higher Med Profess Sch Opole, Fac Hlth Sci, Opole, Poland
[5] Med Univ Silesia, Sch Med, Dept Histol & Embryol, Div Dent, Zabrze, Poland
关键词
Endometrial cancer; endoglin; angiogenesis; molecular marker; vascular endothelium; immunohistochemistry; ENDOTHELIAL GROWTH-FACTOR; TGF-BETA CORECEPTOR; PROGNOSTIC MARKERS; CD105; EXPRESSION; ANGIOGENESIS; CARCINOMA; VASCULATURE; METASTASIS; PREDICTOR; DIAGNOSIS;
D O I
10.2174/1389201020666181127152605
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Endoglin is a marker of active, proliferating endothelial cells of blood vessels. In many cancers, it is present in both peripheral vessels and vessels located inside the tumor. Endoglin is more specific and sensitive compared to other tumor angiogenesis markers. It is suggested that endoglin can be considered a reliable marker of disease outcome. Objective: The aim of the study was to assess the expression of endoglin and to determine its potential usefulness as a complementary molecular marker of endometrial cancer. Method: The study included 60 women who underwent hysterectomy: 45 with endometrioid endometrial cancer (study group) and 15 without neoplastic changes (control group). The study group was further divided according to the degree of histological differentiation: G1, 17; G2, 15; and G3, 13. The expression of endoglin was determined immunohistochemically with mouse anti-Endoglin monoclonal antibody. The obtained reactions were evaluated using light microscopy. Results: Analysis of endoglin expression in endothelium showed that it reached 145% of the control. In G2, we observed that the endoglin level decreased and was similar to the control, while in G3 it increased and was even higher than in G1. In cancer cells, endoglin expression increased with the grade of endometrial cancer. Conclusion: Endoglin can be considered a valuable complementary molecular marker, allowing to visualize the advancement of the cancer process, including endometrial cancer.
引用
收藏
页码:990 / 995
页数:6
相关论文
共 50 条
  • [31] Contribution of Immunohistochemical Profile in Assessing Histological Grade of Endometrial Cancer
    Canlorbe, Geoffroy
    Laas, Enora
    Bendifallah, Sofiane
    Darai, Emile
    Ballester, Marcos
    ANTICANCER RESEARCH, 2013, 33 (05) : 2191 - 2198
  • [32] Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy
    Fujita, Kazutoshi
    Ujike, Takeshi
    Nagahara, Akira
    Uemura, Motohide
    Tanigawa, Go
    Shimazu, Kohki
    Fushimi, Hiroaki
    Yamaguchi, Seiji
    Nonomura, Norio
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (05) : 463 - 467
  • [33] Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades
    Evans, J. J.
    Chitcholtan, K.
    Dann, J. M.
    Guilford, P.
    Harris, Gavin
    Lewis, L. K.
    Nagase, J.
    Welkamp, A. A. W.
    Zwerus, R.
    Sykes, P. H.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 214 - 219
  • [34] Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study
    Althubiti, Mohammad A.
    SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES, 2019, 7 (01) : 16 - 21
  • [35] Overexpression of MMSET in endometrial cancer: A clinicopathologic study
    Xiao, Min
    Yang, Shanshan
    Chen, Jie
    Ning, Xiaoming
    Guo, Liyuan
    Huang, Kejin
    Sui, Lihua
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (04) : 428 - 432
  • [36] High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy
    Rau, Kun-Ming
    Su, Yu-Li
    Li, Shan-Hsuan
    Hsieh, Meng-Che
    Wu, Shis-Chung
    Chou, Fong-Fu
    Chiu, Tai-Jan
    Chen, Yen-Hao
    Liu, Chien-Ting
    MOLECULAR MEDICINE REPORTS, 2017, 16 (05) : 7185 - 7190
  • [37] Endoglin (CD105) expression and angiogenesis status in small cell lung cancer
    Takase, Yukari
    Kai, Keita
    Masuda, Masanori
    Akashi, Michiaki
    Tokunaga, Osamu
    PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (11) : 725 - 730
  • [38] Characterization of endoglin and Ki-67 expression in endothelial cells from benign and malignant lesions of the uterine cervix
    Cimpean, Anca M.
    Saptefrati, Lilian
    Ceausu, Raluca
    Raica, Marius
    PATHOLOGY INTERNATIONAL, 2009, 59 (10) : 695 - 700
  • [39] Angiostatin expression in endometrial cancer
    Yabushita, H
    Noguchi, M
    Kinoshita, S
    Kishida, T
    Sawaguchi, K
    Noguchi, M
    ONCOLOGY REPORTS, 2002, 9 (06) : 1193 - 1196
  • [40] An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
    Gordon, Michael S.
    Robert, Francisco
    Matei, Daniela
    Mendelson, David S.
    Goldman, Jonathan W.
    Chiorean, E. Gabriela
    Strother, Robert M.
    Seon, Ben K.
    Figg, William D.
    Peer, Cody J.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Rosen, Lee S.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5918 - 5926